http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 25 Aug 2026 02:57:40 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Senhwa+completes+enrollment+in+Phase+1b+CX-5461+cancer+trial/26969823.html <p>Senhwa Biosciences, Inc. (TPEx: 6492) announced it has completed enrollment in its Phase 1b expansion trial evaluating pidnarulex (CX-5461) monotherapy in patients with advanced solid tumors carrying BRCA1/2, PALB2, or other homologous recombination deficiency (HRD)-associated alterations.</p> <p>The study will proceed to data review and reconciliation, database lock, and comprehensive statistical analysis. The Clinical Study Report (CSR) is expected in the first quarter of 2027.</p> <p>The trial enrolled patients with advanced pancreatic, breast, and ovarian cancers who had received a median of six prior lines of therapy, with a range of one to 14. Most patients had previously received multiple standard-of-care treatments, including http://www.streetinsider.com/FDA/Senhwa+completes+enrollment+in+Phase+1b+CX-5461+cancer+trial/26969823.html Tue, 25 Aug 2026 02:57:40 -0400 6492 A.50216726 O.14948844 O.21612337 http://www.streetinsider.com/FDA/Senhwa+completes+enrollment+in+Phase+1b+CX-5461+cancer+trial/26969823.html <p>Senhwa Biosciences, Inc. (TPEx: 6492) announced it has completed enrollment in its Phase 1b expansion trial evaluating pidnarulex (CX-5461) monotherapy in patients with advanced solid tumors carrying BRCA1/2, PALB2, or other homologous recombination deficiency (HRD)-associated alterations.</p> <p>The study will proceed to data review and reconciliation, database lock, and comprehensive statistical analysis. The Clinical Study Report (CSR) is expected in the first quarter of 2027.</p> <p>The trial enrolled patients with advanced pancreatic, breast, and ovarian cancers who had received a median of six prior lines of therapy, with a range of one to 14. Most patients had previously received multiple standard-of-care treatments, including http://www.streetinsider.com/FDA/Senhwa+completes+enrollment+in+Phase+1b+CX-5461+cancer+trial/26969823.html Tue, 25 Aug 2026 02:57:40 -0400 6492 A.50216726 O.14948844 O.21612337 http://www.streetinsider.com/FDA/Senhwa+completes+enrollment+in+Phase+1b+CX-5461+cancer+trial/26969823.html <p>Senhwa Biosciences, Inc. (TPEx: 6492) announced it has completed enrollment in its Phase 1b expansion trial evaluating pidnarulex (CX-5461) monotherapy in patients with advanced solid tumors carrying BRCA1/2, PALB2, or other homologous recombination deficiency (HRD)-associated alterations.</p> <p>The study will proceed to data review and reconciliation, database lock, and comprehensive statistical analysis. The Clinical Study Report (CSR) is expected in the first quarter of 2027.</p> <p>The trial enrolled patients with advanced pancreatic, breast, and ovarian cancers who had received a median of six prior lines of therapy, with a range of one to 14. Most patients had previously received multiple standard-of-care treatments, including http://www.streetinsider.com/FDA/Senhwa+completes+enrollment+in+Phase+1b+CX-5461+cancer+trial/26969823.html Tue, 25 Aug 2026 02:57:40 -0400 6492 A.50216726 O.14948844 O.21612337 http://www.streetinsider.com/FDA/Senhwa+completes+enrollment+in+Phase+1b+CX-5461+cancer+trial/26969823.html <p>Senhwa Biosciences, Inc. (TPEx: 6492) announced it has completed enrollment in its Phase 1b expansion trial evaluating pidnarulex (CX-5461) monotherapy in patients with advanced solid tumors carrying BRCA1/2, PALB2, or other homologous recombination deficiency (HRD)-associated alterations.</p> <p>The study will proceed to data review and reconciliation, database lock, and comprehensive statistical analysis. The Clinical Study Report (CSR) is expected in the first quarter of 2027.</p> <p>The trial enrolled patients with advanced pancreatic, breast, and ovarian cancers who had received a median of six prior lines of therapy, with a range of one to 14. Most patients had previously received multiple standard-of-care treatments, including http://www.streetinsider.com/FDA/Senhwa+completes+enrollment+in+Phase+1b+CX-5461+cancer+trial/26969823.html Tue, 25 Aug 2026 02:57:40 -0400 6492 A.50216726 O.14948844 O.21612337 http://www.streetinsider.com/Press+Releases/Senhwa+Completes+Enrollment+in+Phase+1b+CX-5461+Expansion+Trial%3B+CSR+Expected+in+Q1+2027/26969821.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6492" idsrc="xmltag.org" >Senhwa Biosciences, Inc.</span> (TPEx: 6492) today announced that it has completed enrollment in its Phase 1b expansion trial evaluating pidnarulex (CX-5461) monotherapy in patients with advanced solid tumors harboring BRCA1/2, PALB2, or other homologous recombination deficiency (HRD)-associated alterations. With enrollment complete, the study will proceed to data review and reconciliation, database lock, and comprehensive statistical analysis. The Clinical Study Report (CSR) is expected in the first quarter of 2027.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Senhwa+Completes+Enrollment+in+Phase+1b+CX-5461+Expansion+Trial%3B+CSR+Expected+in+Q1+2027/26969821.html Tue, 25 Aug 2026 02:56:00 -0400 6492 6492 A.50216726 O.14948844 O.21612337 http://www.streetinsider.com/Press+Releases/Senhwa+Completes+Enrollment+in+Phase+1b+CX-5461+Expansion+Trial%3B+CSR+Expected+in+Q1+2027/26969821.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6492" idsrc="xmltag.org" >Senhwa Biosciences, Inc.</span> (TPEx: 6492) today announced that it has completed enrollment in its Phase 1b expansion trial evaluating pidnarulex (CX-5461) monotherapy in patients with advanced solid tumors harboring BRCA1/2, PALB2, or other homologous recombination deficiency (HRD)-associated alterations. With enrollment complete, the study will proceed to data review and reconciliation, database lock, and comprehensive statistical analysis. The Clinical Study Report (CSR) is expected in the first quarter of 2027.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Senhwa+Completes+Enrollment+in+Phase+1b+CX-5461+Expansion+Trial%3B+CSR+Expected+in+Q1+2027/26969821.html Tue, 25 Aug 2026 02:56:00 -0400 6492 6492 A.50216726 O.14948844 O.21612337 http://www.streetinsider.com/Press+Releases/Senhwa+Completes+Enrollment+in+Phase+1b+CX-5461+Expansion+Trial%3B+CSR+Expected+in+Q1+2027/26969821.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6492" idsrc="xmltag.org" >Senhwa Biosciences, Inc.</span> (TPEx: 6492) today announced that it has completed enrollment in its Phase 1b expansion trial evaluating pidnarulex (CX-5461) monotherapy in patients with advanced solid tumors harboring BRCA1/2, PALB2, or other homologous recombination deficiency (HRD)-associated alterations. With enrollment complete, the study will proceed to data review and reconciliation, database lock, and comprehensive statistical analysis. The Clinical Study Report (CSR) is expected in the first quarter of 2027.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Senhwa+Completes+Enrollment+in+Phase+1b+CX-5461+Expansion+Trial%3B+CSR+Expected+in+Q1+2027/26969821.html Tue, 25 Aug 2026 02:56:00 -0400 6492 6492 A.50216726 O.14948844 O.21612337 http://www.streetinsider.com/Press+Releases/Senhwa+Completes+Enrollment+in+Phase+1b+CX-5461+Expansion+Trial%3B+CSR+Expected+in+Q1+2027/26969821.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6492" idsrc="xmltag.org" >Senhwa Biosciences, Inc.</span> (TPEx: 6492) today announced that it has completed enrollment in its Phase 1b expansion trial evaluating pidnarulex (CX-5461) monotherapy in patients with advanced solid tumors harboring BRCA1/2, PALB2, or other homologous recombination deficiency (HRD)-associated alterations. With enrollment complete, the study will proceed to data review and reconciliation, database lock, and comprehensive statistical analysis. The Clinical Study Report (CSR) is expected in the first quarter of 2027.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Senhwa+Completes+Enrollment+in+Phase+1b+CX-5461+Expansion+Trial%3B+CSR+Expected+in+Q1+2027/26969821.html Tue, 25 Aug 2026 02:56:00 -0400 6492 6492 A.50216726 O.14948844 O.21612337 http://www.streetinsider.com/Press+Releases/Senhwa+Completes+Enrollment+in+Phase+1b+CX-5461+Expansion+Trial%3B+CSR+Expected+in+Q1+2027/26969821.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6492" idsrc="xmltag.org" >Senhwa Biosciences, Inc.</span> (TPEx: 6492) today announced that it has completed enrollment in its Phase 1b expansion trial evaluating pidnarulex (CX-5461) monotherapy in patients with advanced solid tumors harboring BRCA1/2, PALB2, or other homologous recombination deficiency (HRD)-associated alterations. With enrollment complete, the study will proceed to data review and reconciliation, database lock, and comprehensive statistical analysis. The Clinical Study Report (CSR) is expected in the first quarter of 2027.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Senhwa+Completes+Enrollment+in+Phase+1b+CX-5461+Expansion+Trial%3B+CSR+Expected+in+Q1+2027/26969821.html Tue, 25 Aug 2026 02:56:00 -0400 6492 6492 A.50216726 O.14948844 O.21612337 http://www.streetinsider.com/PRNewswire/Senhwa+Completes+Enrollment+in+Phase+1b+CX-5461+Expansion+Trial%3B+CSR+Expected+in+Q1+2027/26969821.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6492" idsrc="xmltag.org" >Senhwa Biosciences, Inc.</span> (TPEx: 6492) today announced that it has completed enrollment in its Phase 1b expansion trial evaluating pidnarulex (CX-5461) monotherapy in patients with advanced solid tumors harboring BRCA1/2, PALB2, or other homologous recombination deficiency (HRD)-associated alterations. With enrollment complete, the study will proceed to data review and reconciliation, database lock, and comprehensive statistical analysis. The Clinical Study Report (CSR) is expected in the first quarter of 2027.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Senhwa+Completes+Enrollment+in+Phase+1b+CX-5461+Expansion+Trial%3B+CSR+Expected+in+Q1+2027/26969821.html Tue, 25 Aug 2026 02:56:00 -0400 6492 6492 A.50216726 O.14948844 O.21612337 http://www.streetinsider.com/PRNewswire/Senhwa+Completes+Enrollment+in+Phase+1b+CX-5461+Expansion+Trial%3B+CSR+Expected+in+Q1+2027/26969821.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6492" idsrc="xmltag.org" >Senhwa Biosciences, Inc.</span> (TPEx: 6492) today announced that it has completed enrollment in its Phase 1b expansion trial evaluating pidnarulex (CX-5461) monotherapy in patients with advanced solid tumors harboring BRCA1/2, PALB2, or other homologous recombination deficiency (HRD)-associated alterations. With enrollment complete, the study will proceed to data review and reconciliation, database lock, and comprehensive statistical analysis. The Clinical Study Report (CSR) is expected in the first quarter of 2027.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Senhwa+Completes+Enrollment+in+Phase+1b+CX-5461+Expansion+Trial%3B+CSR+Expected+in+Q1+2027/26969821.html Tue, 25 Aug 2026 02:56:00 -0400 6492 6492 A.50216726 O.14948844 O.21612337 http://www.streetinsider.com/PRNewswire/Senhwa+Completes+Enrollment+in+Phase+1b+CX-5461+Expansion+Trial%3B+CSR+Expected+in+Q1+2027/26969821.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6492" idsrc="xmltag.org" >Senhwa Biosciences, Inc.</span> (TPEx: 6492) today announced that it has completed enrollment in its Phase 1b expansion trial evaluating pidnarulex (CX-5461) monotherapy in patients with advanced solid tumors harboring BRCA1/2, PALB2, or other homologous recombination deficiency (HRD)-associated alterations. With enrollment complete, the study will proceed to data review and reconciliation, database lock, and comprehensive statistical analysis. The Clinical Study Report (CSR) is expected in the first quarter of 2027.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Senhwa+Completes+Enrollment+in+Phase+1b+CX-5461+Expansion+Trial%3B+CSR+Expected+in+Q1+2027/26969821.html Tue, 25 Aug 2026 02:56:00 -0400 6492 6492 A.50216726 O.14948844 O.21612337 http://www.streetinsider.com/PRNewswire/Senhwa+Completes+Enrollment+in+Phase+1b+CX-5461+Expansion+Trial%3B+CSR+Expected+in+Q1+2027/26969821.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6492" idsrc="xmltag.org" >Senhwa Biosciences, Inc.</span> (TPEx: 6492) today announced that it has completed enrollment in its Phase 1b expansion trial evaluating pidnarulex (CX-5461) monotherapy in patients with advanced solid tumors harboring BRCA1/2, PALB2, or other homologous recombination deficiency (HRD)-associated alterations. With enrollment complete, the study will proceed to data review and reconciliation, database lock, and comprehensive statistical analysis. The Clinical Study Report (CSR) is expected in the first quarter of 2027.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Senhwa+Completes+Enrollment+in+Phase+1b+CX-5461+Expansion+Trial%3B+CSR+Expected+in+Q1+2027/26969821.html Tue, 25 Aug 2026 02:56:00 -0400 6492 6492 A.50216726 O.14948844 O.21612337 http://www.streetinsider.com/PRNewswire/Senhwa+Completes+Enrollment+in+Phase+1b+CX-5461+Expansion+Trial%3B+CSR+Expected+in+Q1+2027/26969821.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Aug. 25, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6492" idsrc="xmltag.org" >Senhwa Biosciences, Inc.</span> (TPEx: 6492) today announced that it has completed enrollment in its Phase 1b expansion trial evaluating pidnarulex (CX-5461) monotherapy in patients with advanced solid tumors harboring BRCA1/2, PALB2, or other homologous recombination deficiency (HRD)-associated alterations. With enrollment complete, the study will proceed to data review and reconciliation, database lock, and comprehensive statistical analysis. The Clinical Study Report (CSR) is expected in the first quarter of 2027.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Senhwa+Completes+Enrollment+in+Phase+1b+CX-5461+Expansion+Trial%3B+CSR+Expected+in+Q1+2027/26969821.html Tue, 25 Aug 2026 02:56:00 -0400 6492 6492 A.50216726 O.14948844 O.21612337 http://www.streetinsider.com/Press+Releases/Senhwa%27s+CX-5461+Opens+a+New+Frontier+in+Photoimmunotherapy%3B+Multinational+Study+Published+in+Nucleic+Acids+Research/26907833.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location> and <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 12, 2026</chron></span> /PRNewswire/ -- Senhwa<span> <span>Biosciences, Inc.</span> (</span>TPEx<span>: 6492) today announced a significant research advance involving its investigational drug </span>Pidnarulex<span> (CX-5461). A multinational research team comprising investigators from <location value="LC/pl" idsrc="xmltag.org" >Poland</location>, <location value="LC/sk" idsrc="xmltag.org" >Slovakia</location>, <location value="LC/fr" idsrc="xmltag.org" >France</location> and </span>Senhwa<span> Biosciences in <location value="LC/tw" idsrc="xmltag.org" >Taiwan</location> found that, under specific cell-based experimental conditions, controlled light activation increased the cancer-cell-killing activity of CX-5461 by up to 96-fold and induced </span>immunogenic<span> cell death (</span>ICD<span>). The findings, published in the peer-reviewed journal </span><i><span>Nucleic Acids Research</span></i><span>, reveal that http://www.streetinsider.com/Press+Releases/Senhwa%27s+CX-5461+Opens+a+New+Frontier+in+Photoimmunotherapy%3B+Multinational+Study+Published+in+Nucleic+Acids+Research/26907833.html Wed, 12 Aug 2026 03:01:00 -0400 6492 6492 http://www.streetinsider.com/Press+Releases/Senhwa%27s+CX-5461+Opens+a+New+Frontier+in+Photoimmunotherapy%3B+Multinational+Study+Published+in+Nucleic+Acids+Research/26907833.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location> and <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 12, 2026</chron></span> /PRNewswire/ -- Senhwa<span> <span>Biosciences, Inc.</span> (</span>TPEx<span>: 6492) today announced a significant research advance involving its investigational drug </span>Pidnarulex<span> (CX-5461). A multinational research team comprising investigators from <location value="LC/pl" idsrc="xmltag.org" >Poland</location>, <location value="LC/sk" idsrc="xmltag.org" >Slovakia</location>, <location value="LC/fr" idsrc="xmltag.org" >France</location> and </span>Senhwa<span> Biosciences in <location value="LC/tw" idsrc="xmltag.org" >Taiwan</location> found that, under specific cell-based experimental conditions, controlled light activation increased the cancer-cell-killing activity of CX-5461 by up to 96-fold and induced </span>immunogenic<span> cell death (</span>ICD<span>). The findings, published in the peer-reviewed journal </span><i><span>Nucleic Acids Research</span></i><span>, reveal that http://www.streetinsider.com/Press+Releases/Senhwa%27s+CX-5461+Opens+a+New+Frontier+in+Photoimmunotherapy%3B+Multinational+Study+Published+in+Nucleic+Acids+Research/26907833.html Wed, 12 Aug 2026 03:01:00 -0400 6492 6492 http://www.streetinsider.com/PRNewswire/Senhwa%27s+CX-5461+Opens+a+New+Frontier+in+Photoimmunotherapy%3B+Multinational+Study+Published+in+Nucleic+Acids+Research/26907833.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location> and <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 12, 2026</chron></span> /PRNewswire/ -- Senhwa<span> <span>Biosciences, Inc.</span> (</span>TPEx<span>: 6492) today announced a significant research advance involving its investigational drug </span>Pidnarulex<span> (CX-5461). A multinational research team comprising investigators from <location value="LC/pl" idsrc="xmltag.org" >Poland</location>, <location value="LC/sk" idsrc="xmltag.org" >Slovakia</location>, <location value="LC/fr" idsrc="xmltag.org" >France</location> and </span>Senhwa<span> Biosciences in <location value="LC/tw" idsrc="xmltag.org" >Taiwan</location> found that, under specific cell-based experimental conditions, controlled light activation increased the cancer-cell-killing activity of CX-5461 by up to 96-fold and induced </span>immunogenic<span> cell death (</span>ICD<span>). The findings, published in the peer-reviewed journal </span><i><span>Nucleic Acids Research</span></i><span>, reveal that http://www.streetinsider.com/PRNewswire/Senhwa%27s+CX-5461+Opens+a+New+Frontier+in+Photoimmunotherapy%3B+Multinational+Study+Published+in+Nucleic+Acids+Research/26907833.html Wed, 12 Aug 2026 03:01:00 -0400 6492 6492 http://www.streetinsider.com/PRNewswire/Senhwa%27s+CX-5461+Opens+a+New+Frontier+in+Photoimmunotherapy%3B+Multinational+Study+Published+in+Nucleic+Acids+Research/26907833.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location> and <location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>Aug. 12, 2026</chron></span> /PRNewswire/ -- Senhwa<span> <span>Biosciences, Inc.</span> (</span>TPEx<span>: 6492) today announced a significant research advance involving its investigational drug </span>Pidnarulex<span> (CX-5461). A multinational research team comprising investigators from <location value="LC/pl" idsrc="xmltag.org" >Poland</location>, <location value="LC/sk" idsrc="xmltag.org" >Slovakia</location>, <location value="LC/fr" idsrc="xmltag.org" >France</location> and </span>Senhwa<span> Biosciences in <location value="LC/tw" idsrc="xmltag.org" >Taiwan</location> found that, under specific cell-based experimental conditions, controlled light activation increased the cancer-cell-killing activity of CX-5461 by up to 96-fold and induced </span>immunogenic<span> cell death (</span>ICD<span>). The findings, published in the peer-reviewed journal </span><i><span>Nucleic Acids Research</span></i><span>, reveal that http://www.streetinsider.com/PRNewswire/Senhwa%27s+CX-5461+Opens+a+New+Frontier+in+Photoimmunotherapy%3B+Multinational+Study+Published+in+Nucleic+Acids+Research/26907833.html Wed, 12 Aug 2026 03:01:00 -0400 6492 6492 http://www.streetinsider.com/Press+Releases/Senhwa%27s+CX-5461+Reaches+Immuno-Oncology+Milestone+as+its+First+Multicenter+Combination+Trial+with+PD-1+Inhibitor+Receives+TFDA+Clearance/26877128.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6492" idsrc="xmltag.org" >Senhwa Biosciences, Inc.</span> (TPEx: 6492) today announced that the <span>Taiwan Food and Drug Administration</span> (TFDA) has cleared the Company's multicenter Phase 1b/2a clinical trial evaluating its investigational drug pidnarulex (CX-5461) in combination with a marketed PD-1 immune checkpoint inhibitor. The TFDA clearance follows clearance by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) in <chron>June 2026</chron>, enabling the study to proceed in both <location value="LC/tw" idsrc="xmltag.org" >Taiwan</location> and <location value="LC/us" idsrc="xmltag.org" >the United States</location>. This marks an important step in the http://www.streetinsider.com/Press+Releases/Senhwa%27s+CX-5461+Reaches+Immuno-Oncology+Milestone+as+its+First+Multicenter+Combination+Trial+with+PD-1+Inhibitor+Receives+TFDA+Clearance/26877128.html Thu, 06 Aug 2026 05:14:00 -0400 6492 6492 A.06822034 O.14948844 O.20026344 http://www.streetinsider.com/Press+Releases/Senhwa%27s+CX-5461+Reaches+Immuno-Oncology+Milestone+as+its+First+Multicenter+Combination+Trial+with+PD-1+Inhibitor+Receives+TFDA+Clearance/26877128.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6492" idsrc="xmltag.org" >Senhwa Biosciences, Inc.</span> (TPEx: 6492) today announced that the <span>Taiwan Food and Drug Administration</span> (TFDA) has cleared the Company's multicenter Phase 1b/2a clinical trial evaluating its investigational drug pidnarulex (CX-5461) in combination with a marketed PD-1 immune checkpoint inhibitor. The TFDA clearance follows clearance by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) in <chron>June 2026</chron>, enabling the study to proceed in both <location value="LC/tw" idsrc="xmltag.org" >Taiwan</location> and <location value="LC/us" idsrc="xmltag.org" >the United States</location>. This marks an important step in the http://www.streetinsider.com/Press+Releases/Senhwa%27s+CX-5461+Reaches+Immuno-Oncology+Milestone+as+its+First+Multicenter+Combination+Trial+with+PD-1+Inhibitor+Receives+TFDA+Clearance/26877128.html Thu, 06 Aug 2026 05:14:00 -0400 6492 6492 A.06822034 O.14948844 O.20026344 http://www.streetinsider.com/Press+Releases/Senhwa%27s+CX-5461+Reaches+Immuno-Oncology+Milestone+as+its+First+Multicenter+Combination+Trial+with+PD-1+Inhibitor+Receives+TFDA+Clearance/26877128.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6492" idsrc="xmltag.org" >Senhwa Biosciences, Inc.</span> (TPEx: 6492) today announced that the <span>Taiwan Food and Drug Administration</span> (TFDA) has cleared the Company's multicenter Phase 1b/2a clinical trial evaluating its investigational drug pidnarulex (CX-5461) in combination with a marketed PD-1 immune checkpoint inhibitor. The TFDA clearance follows clearance by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) in <chron>June 2026</chron>, enabling the study to proceed in both <location value="LC/tw" idsrc="xmltag.org" >Taiwan</location> and <location value="LC/us" idsrc="xmltag.org" >the United States</location>. This marks an important step in the http://www.streetinsider.com/Press+Releases/Senhwa%27s+CX-5461+Reaches+Immuno-Oncology+Milestone+as+its+First+Multicenter+Combination+Trial+with+PD-1+Inhibitor+Receives+TFDA+Clearance/26877128.html Thu, 06 Aug 2026 05:14:00 -0400 6492 6492 A.06822034 O.14948844 O.20026344 http://www.streetinsider.com/Press+Releases/Senhwa%27s+CX-5461+Reaches+Immuno-Oncology+Milestone+as+its+First+Multicenter+Combination+Trial+with+PD-1+Inhibitor+Receives+TFDA+Clearance/26877128.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6492" idsrc="xmltag.org" >Senhwa Biosciences, Inc.</span> (TPEx: 6492) today announced that the <span>Taiwan Food and Drug Administration</span> (TFDA) has cleared the Company's multicenter Phase 1b/2a clinical trial evaluating its investigational drug pidnarulex (CX-5461) in combination with a marketed PD-1 immune checkpoint inhibitor. The TFDA clearance follows clearance by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) in <chron>June 2026</chron>, enabling the study to proceed in both <location value="LC/tw" idsrc="xmltag.org" >Taiwan</location> and <location value="LC/us" idsrc="xmltag.org" >the United States</location>. This marks an important step in the http://www.streetinsider.com/Press+Releases/Senhwa%27s+CX-5461+Reaches+Immuno-Oncology+Milestone+as+its+First+Multicenter+Combination+Trial+with+PD-1+Inhibitor+Receives+TFDA+Clearance/26877128.html Thu, 06 Aug 2026 05:14:00 -0400 6492 6492 A.06822034 O.14948844 O.20026344 http://www.streetinsider.com/Press+Releases/Senhwa%27s+CX-5461+Reaches+Immuno-Oncology+Milestone+as+its+First+Multicenter+Combination+Trial+with+PD-1+Inhibitor+Receives+TFDA+Clearance/26877128.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6492" idsrc="xmltag.org" >Senhwa Biosciences, Inc.</span> (TPEx: 6492) today announced that the <span>Taiwan Food and Drug Administration</span> (TFDA) has cleared the Company's multicenter Phase 1b/2a clinical trial evaluating its investigational drug pidnarulex (CX-5461) in combination with a marketed PD-1 immune checkpoint inhibitor. The TFDA clearance follows clearance by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) in <chron>June 2026</chron>, enabling the study to proceed in both <location value="LC/tw" idsrc="xmltag.org" >Taiwan</location> and <location value="LC/us" idsrc="xmltag.org" >the United States</location>. This marks an important step in the http://www.streetinsider.com/Press+Releases/Senhwa%27s+CX-5461+Reaches+Immuno-Oncology+Milestone+as+its+First+Multicenter+Combination+Trial+with+PD-1+Inhibitor+Receives+TFDA+Clearance/26877128.html Thu, 06 Aug 2026 05:14:00 -0400 6492 6492 A.06822034 O.14948844 O.20026344 http://www.streetinsider.com/PRNewswire/Senhwa%27s+CX-5461+Reaches+Immuno-Oncology+Milestone+as+its+First+Multicenter+Combination+Trial+with+PD-1+Inhibitor+Receives+TFDA+Clearance/26877128.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6492" idsrc="xmltag.org" >Senhwa Biosciences, Inc.</span> (TPEx: 6492) today announced that the <span>Taiwan Food and Drug Administration</span> (TFDA) has cleared the Company's multicenter Phase 1b/2a clinical trial evaluating its investigational drug pidnarulex (CX-5461) in combination with a marketed PD-1 immune checkpoint inhibitor. The TFDA clearance follows clearance by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) in <chron>June 2026</chron>, enabling the study to proceed in both <location value="LC/tw" idsrc="xmltag.org" >Taiwan</location> and <location value="LC/us" idsrc="xmltag.org" >the United States</location>. This marks an important step in the http://www.streetinsider.com/PRNewswire/Senhwa%27s+CX-5461+Reaches+Immuno-Oncology+Milestone+as+its+First+Multicenter+Combination+Trial+with+PD-1+Inhibitor+Receives+TFDA+Clearance/26877128.html Thu, 06 Aug 2026 05:14:00 -0400 6492 6492 A.06822034 O.14948844 O.20026344 http://www.streetinsider.com/PRNewswire/Senhwa%27s+CX-5461+Reaches+Immuno-Oncology+Milestone+as+its+First+Multicenter+Combination+Trial+with+PD-1+Inhibitor+Receives+TFDA+Clearance/26877128.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/tw..taipei" idsrc="xmltag.org" >TAIPEI</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- <span value="Gretai:6492" idsrc="xmltag.org" >Senhwa Biosciences, Inc.</span> (TPEx: 6492) today announced that the <span>Taiwan Food and Drug Administration</span> (TFDA) has cleared the Company's multicenter Phase 1b/2a clinical trial evaluating its investigational drug pidnarulex (CX-5461) in combination with a marketed PD-1 immune checkpoint inhibitor. The TFDA clearance follows clearance by the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) in <chron>June 2026</chron>, enabling the study to proceed in both <location value="LC/tw" idsrc="xmltag.org" >Taiwan</location> and <location value="LC/us" idsrc="xmltag.org" >the United States</location>. This marks an important step in the http://www.streetinsider.com/PRNewswire/Senhwa%27s+CX-5461+Reaches+Immuno-Oncology+Milestone+as+its+First+Multicenter+Combination+Trial+with+PD-1+Inhibitor+Receives+TFDA+Clearance/26877128.html Thu, 06 Aug 2026 05:14:00 -0400 6492 6492 A.06822034 O.14948844 O.20026344